Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates

Vaccine

Volumn 28, Issue 2, 2009, Pages 494-511

  Hooper, Jay W ^a   Ferro, Anthony M ^a   Golden, Joseph W ^a   Silvera, Peter ^b   Dudek, Jeanne ^c   Alterson, Kim ^d   Custer, Max ^d   Rivers, Bryan ^d   Morris, John ^d   Owens, Gary ^d   Smith, Jonathan F ^d   Kamrud, Kurt I ^d  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c Life Technologies   (United States)

^d AlphaVax Inc   (United States)

Author keywords

Alphavirus replicon; Monkeypox; Neutralizing antibodies; Non human primate; Smallpox; Vaccine; Vaccinia

Indexed keywords

ALPHAVIRUS REPLICON VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS VACCINE;

ALPHA VIRUS; ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; GENE EXPRESSION; IMMUNITY; MONKEYPOX VIRUS; NONHUMAN; POXVIRUS; PRIMATE; PRIORITY JOURNAL; SMALLPOX; VACCINATION; VACCINIA VIRUS; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

ALPHAVIRUS; ANIMALS; ANTIBODIES, NEUTRALIZING; CERCOPITHECUS AETHIOPS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MACACA; MICE; MICE, INBRED BALB C; POLYMERASE CHAIN REACTION; SMALLPOX VACCINE; VERO CELLS;

EID: 70749112819     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.133     Document Type: Article

References (71)

1. Bray M. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res 58 April (2) (2003) 101-114
2. Lane J.M., and Goldstein J. Adverse events occurring after smallpox vaccination. Semin Pediatr Infect Dis 14 July (3) (2003) 189-195
3. Artenstein A.W., and Grabenstein J.D. Smallpox vaccines for biodefense: need and feasibility. Expert Rev Vaccines 7 October (8) (2008) 1225-1237
4. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Whitbeck J.C., Cohen G.H., et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428 March (6979) (2004) 182-185
5. McCurdy L.H., Larkin B.D., Martin J.E., and Graham B.S. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin Infect Dis 38 June (12) (2004) 1749-1753
6. Stittelaar K.J., van Amerongen G., Kondova I., Kuiken T., van Lavieren R.F., Pistoor F.H., et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 79 June (12) (2005) 7845-7851
7. Hashizume S, Yoshizawa H, Morita M, Suzuki Kp-IGVQe, Vaccinia viruses as vectors for vaccine antigens. Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain. In: Quainnan GV, editor. Vaccinia viruses as vectors for vaccine antigens. Amsterdam, Netherlands: Elsevier Science Publishing Co.; 1985. p. 421-8.
8. Kenner J., Cameron F., Empig C., Jobes D.V., and Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 24 November (47-48) (2006) 7009-7022
9. Davies D.H., McCausland M.M., Valdez C., Huynh D., Hernandez J.E., Mu Y., et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol 79 September (18) (2005) 11724-11733
10. Demkowicz W.E., Maa J.S., and Esteban M. Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans. J Virol 66 January (1) (1992) 386-398
11. Fang M., Cheng H., Dai Z., Bu Z., and Sigal L.J. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology 345 February (1) (2006) 231-243
12. Fogg C., Lustig S., Whitbeck J.C., Eisenberg R.J., Cohen G.H., and Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol 78 October (19) (2004) 10230-10237
13. Galmiche M.C., Goenaga J., Wittek R., and Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254 February (1) (1999) 71-80
14. Heraud J.M., Edghill-Smith Y., Ayala V., Kalisz I., Parrino J., Kalyanaraman V.S., et al. Subunit recombinant vaccine protects against monkeypox. J Immunol 177 August (4) (2006) 2552-2564
15. Hooper J.W., Custer D.M., Schmaljohn C.S., and Schmaljohn A.L. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266 January (2) (2000) 329-339
16. Hooper J.W., Custer D.M., and Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306 February (1) (2003) 181-195
17. Hooper J.W., Golden J.W., Ferro A.M., and King A.D. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 25 February (10) (2007) 1814-1823
18. Kaufman D.R., Goudsmit J., Holterman L., Ewald B.A., Denholtz M., Devoy C., et al. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice. J Virol 82 July (14) (2008) 6829-6837
19. Lai C.F., Gong S.C., and Esteban M. The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals. J Virol 65 October (10) (1991) 5631-5635
20. Pulford D.J., Gates A., Bridge S.H., Robinson J.H., and Ulaeto D. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine 22 September (25-26) (2004) 3358-3366
21. Sakhatskyy P., Wang S., Chou T.H., and Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 355 November (2) (2006) 164-174
22. Thornburg N.J., Ray C.A., Collier M.L., Liao H.X., Pickup D.J., and Johnston R.E. Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge. Virology 362 June (2) (2007) 441-452
23. Otero M., Calarota S.A., Dai A., De Groot A.S., Boyer J.D., and Weiner D.B. Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy. Vaccine 24 May (21) (2006) 4461-4470
24. Roberts K.L., and Smith G.L. Vaccinia virus morphogenesis and dissemination. Trends Microbiol 16 October (10) (2008) 472-479
25. Golden J.W., and Hooper J.W. Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine. Virology 377 July (1) (2008) 19-29
26. Golden J.W., Josleyn M.D., and Hooper J.W. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Vaccine 26 June (27-28) (2008) 3507-3515
27. Xu R.H., Cohen M., Tang Y., Lazear E., Whitbeck J.C., Eisenberg R.J., et al. The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. J Exp Med 205 April (4) (2008) 981-992
28. Snyder J.T., Belyakov I.M., Dzutsev A., Lemonnier F., and Berzofsky J.A. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J Virol 78 July (13) (2004) 7052-7060
29. Hooper J.W., Thompson E., Wilhelmsen C., Zimmerman M., Ichou M.A., Steffen S.E., et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol 78 May (9) (2004) 4433-4443
30. Bernard K.A., Klimstra W.B., and Johnston R.E. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276 October (1) (2000) 93-103
31. Pushko P., Parker M., Ludwig G.V., Davis N.L., Johnston R.E., and Smith J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239 December (2) (1997) 389-401
32. Kamrud K.I., Custer M., Dudek J.M., Owens G., Alterson K.D., Lee J.S., et al. Alphavirus replicon approach to promoterless analysis of IRES elements. Virology 360 April (2) (2007) 376-387
33. Kinney R.M., Johnson B.J., Welch J.B., Tsuchiya K.R., and Trent D.W. The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83. Virology 170 May (1) (1989) 19-30
34. Edghill-Smith Y., Golding H., Manischewitz J., King L.R., Scott D., Bray M., et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 11 July (7) (2005) 740-747
35. Panchanathan V., Chaudhri G., and Karupiah G. Interferon function is not required for recovery from a secondary poxvirus infection. Proc Natl Acad Sci USA 102 September (36) (2005) 12921-12926
36. Panchanathan V., Chaudhri G., and Karupiah G. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J Virol 80 July (13) (2006) 6333-6338
37. Panchanathan V., Chaudhri G., and Karupiah G. Correlates of protective immunity in poxvirus infection: where does antibody stand?. Immunol Cell Biol October (2007)
38. Su H.P., Golden J.W., Gittis A.G., Hooper J.W., and Garboczi D.N. Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology August (2007)
39. Hubby B., Talarico T., Maughan M., Reap E.A., Berglund P., Kamrud K.I., et al. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 25 November (48) (2007) 8180-8189
40. Fogg C.N., Americo J.L., Lustig S., Huggins J.W., Smith S.K., Damon I., et al. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine 25 April (15) (2007) 2787-2799
41. Roper R.L., Payne L.G., and Moss B. Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene. J Virol 70 June (6) (1996) 3753-3762
42. Newsome T.P., Scaplehorn N., and Way M. SRC mediates a switch from microtubule- to actin-based motility of vaccinia virus. Science (New York, NY) 306 October (5693) (2004) 124-129
43. Chen Z., Earl P., Americo J., Damon I., Smith S.K., Yu F., et al. Characterization of chimpanzee/human monoclonal antibodies to the vaccinia A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia mouse protection model. J Virol June (2007)
44. Lustig S., Fogg C., Whitbeck J.C., Eisenberg R.J., Cohen G.H., and Moss B. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J Virol 79 November (21) (2005) 13454-13462
45. Lustig S., Fogg C., Whitbeck J.C., and Moss B. Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology 328 October (1) (2004) 30-35
46. Engelstad M., and Smith G.L. The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology 194 June (2) (1993) 627-637
47. Isaacs S.N., Wolffe E.J., Payne L.G., and Moss B. Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. J Virol 66 December (12) (1992) 7217-7224
48. Law M., Carter G.C., Roberts K.L., Hollinshead M., and Smith G.L. Ligand-induced and nonfusogenic dissolution of a viral membrane. Proc Natl Acad Sci USA 103 April (15) (2006) 5989-5994
49. Golovkin M., Spitsin S., Andrianov V., Smirnov Y., Xiao Y., Pogrebnyak N., et al. Smallpox subunit vaccine produced in Planta confers protection in mice. Proc Natl Acad Sci USA 104 April (16) (2007) 6864-6869
50. Law M., and Smith G.L. Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology 280 February (1) (2001) 132-142
51. Aldaz-Carroll L., Whitbeck J.C., Ponce de Leon M., Lou H., Hirao L., Isaacs S.N., et al. Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol 79 May (10) (2005) 6260-6271
52. Chen Z., Earl P., Americo J., Damon I., Smith S.K., Zhou Y.H., et al. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci USA 103 February (6) (2006) 1882-1887
53. Chappell S.A., Edelman G.M., and Mauro V.P. A 9-nt segment of a cellular mRNA can function as an internal ribosome entry site (IRES) and when present in linked multiple copies greatly enhances IRES activity. Proc Natl Acad Sci USA 97 February (4) (2000) 1536-1541
54. Chappell S.A., Edelman G.M., and Mauro V.P. Biochemical and functional analysis of a 9-nt RNA sequence that affects translation efficiency in eukaryotic cells. Proc Natl Acad Sci USA 101 June (26) (2004) 9590-9594
55. Benhnia M.R., McCausland M.M., Moyron J., Laudenslager J., Granger S., Rickert S., et al. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol 83 February (3) (2009) 1201-1215
56. Moss B. Poxviruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields virology. 4th ed. (2001), Lippencott, Williams and Wilkins, Philadelphia 1249-1281
57. Wolffe E.J., Vijaya S., and Moss B. A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 211 August (1) (1995) 53-63
58. Shinoda K., Wyatt L.S., Irvine K.R., and Moss B. Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization. Virol J 6 (2009) 28
59. Rodriguez J.F., Paez E., and Esteban M. A 14,000-Mr envelope protein of vaccinia virus is involved in cell fusion and forms covalently linked trimers. J Virology 61 February (2) (1987) 395-404
60. Grieder F.B., Davis N.L., Aronson J.F., Charles P.C., Sellon D.C., Suzuki K., et al. Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology 206 February (2) (1995) 994-1006
61. Balasuriya U.B., Heidner H.W., Davis N.L., Wagner H.M., Hullinger P.J., Hedges J.F., et al. Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. Vaccine 20 February (11-12) (2002) 1609-1617
62. Balasuriya U.B., Heidner H.W., Hedges J.F., Williams J.C., Davis N.L., Johnston R.E., et al. Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles. J Virol 74 November (22) (2000) 10623-10630
63. Hevey M., Negley D., Pushko P., Smith J., and Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251 November (1) (1998) 28-37
64. Kamrud K.I., Alterson K.D., Andrews C., Copp L.O., Lewis W.C., Hubby B., et al. Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats. PLoS ONE 3 7 (2008) e2709
65. Lee J.S., Dyas B.K., Nystrom S.S., Lind C.M., Smith J.F., and Ulrich R.G. Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon. J Infect Dis 185 April (8) (2002) 1192-1196
66. Pushko P., Bray M., Ludwig G.V., Parker M., Schmaljohn A., Sanchez A., et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19 August (1) (2000) 142-153
67. Pushko P., Geisbert J., Parker M., Jahrling P., and Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 75 December (23) (2001) 11677-11685
68. Reap E.A., Dryga S.A., Morris J., Rivers B., Norberg P.K., Olmsted R.A., et al. Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins. Clin Vaccine Immunol 14 June (6) (2007) 748-755
69. Bernstein D.I., Reap E.R., Katen K., Watson A., Smith K., Norberg P., et al. Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28 (2010) 484-493
70. Burke D.S., Ramsburg H.H., and Edelman R. Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attenuated (TC-83) VEE virus vaccine. J Infect Dis 136 September (3) (1977) 354-359
71. Pittman P.R., Makuch R.S., Mangiafico J.A., Cannon T.L., Gibbs P.H., and Peters C.J. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14 March (4) (1996) 337-343